Statins for the primary prevention of cardiovascular disease

Taylor, Fiona; Huffman, Mark D; Macedo, Ana Filipa; Moore, Theresa HM; Burke, Margaret; Davey Smith, George; Ward, Kirsten; Ebrahim, Shah; Gay, Hawkins C

doi:10.1002/14651858.cd004816.pub5

Cited by 1,934Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismHealth Promotion and Cardiovascular Prevention

Statins for the primary prevention of cardiovascular disease

Open access

Taylor, Fiona, Huffman, Mark D, Macedo, Ana Filipa, Moore, Theresa HM, Burke, Margaret, Davey Smith, George, Ward, Kirsten, Ebrahim, Shah +1 more·2013·Cochrane Database of Systematic Reviews

DOI 10.1002/14651858.cd004816.pub5PMC PMC6481400

Open this paper in CoChat — free account Open PDF

Abstract

Background Reducing high blood cholesterol, a risk factor for cardiovascular disease (CVD) events in people with and without a past history of CVD is an important goal of pharmacotherapy. Statins are the first-choice agents. Previous reviews of the effects of statins have highlighted their benefits in people with CVD. The case for primary prevention was uncertain when the last version of this review was published (2011) and in light of new data an update of this review is required. Objectives To assess the effects, both harms and benefits, of statins in people with no history of CVD. Search methods To avoid duplication of effort, we checked reference lists of previous systematic reviews. The searches conducted in 2007 were updated in January 2012. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2022, Issue 4), MEDLINE OVID (1950 to December Week 4 2011) and EMBASE OVID (1980 to 2012 Week 1).There were no language restrictions. Selection criteria We included randomised controlled trials of statins versus placebo or usual care control with minimum treatment duration of one year and follow-up of six months, in adults with no restrictions on total, low density lipoprotein (LDL) or high density lipoprotein (HDL) cholesterol levels, and where 10% or less had a history of CVD. Data collection and analysis Two review authors independently selected studies for inclusion and extracted data. Outcomes included all-cause mortality, fatal a…

Integrity signals

Registry

Crossref · 10.1002/14651858.cd004816.pub5

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Absolute reductions in ASCVD outcomes (CHD death and nonfatal MI) are greatest in people with high baseline ASCVD risk (known ASCVD and/or very high LDL cholesterol levels), but the overall benefits of statin therapy in people with diabetes at moderate or even low risk for ASCVD are convincing.
“As in those without diabetes, absolute reductions in ASCVD outcomes (CHD death and nonfatal MI) are greatest in people with high baseline ASCVD risk (known ASCVD and/or very high LDL cholesterol levels), but the overall benefits of statin therapy in people with diabetes at moderate or even low risk for ASCVD are convincing (110,111).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [110]
Overall benefits of statin therapy in people with diabetes at moderate or even low risk for ASCVD are convincing.
“As in those without diabetes, absolute reductions in ASCVD outcomes (CHD death and nonfatal MI) are greatest in people with high baseline ASCVD risk (known ASCVD and/or very high LDL cholesterol levels), but the overall benefits of statin therapy in people with diabetes at moderate or even low risk for ASCVD are convincing (102,103).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [102]
Absolute reductions in ASCVD outcomes (CHD death and nonfatal MI) are greatest in people with high baseline ASCVD risk (known ASCVD and/or very high LDL cholesterol levels).
“As in those without diabetes, absolute reductions in ASCVD outcomes (CHD death and nonfatal MI) are greatest in people with high baseline ASCVD risk (known ASCVD and/or very high LDL cholesterol levels), but the overall benefits of statin therapy in people with diabetes at moderate or even low risk for ASCVD are convincing (102,103).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [102]

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490 · see citing works
Self-citation
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449 · see citing works
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · see citing works
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236 · see citing works
Association between Multiple Cardiovascular Risk Factors and Atherosclerosis in Children and Young Adults
Berenson, G. S., Srinivasan, S. R., Bao, W., Newman, W. P., Tracy, R. E., & Wattigney, W. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382302 · Cited by 4,032 · see citing works
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549 · see citing works
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887 · see citing works
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436 · see citing works
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557 · see citing works
Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001 · see citing works
Lifetime risks of cardiovascular disease
Berry, J. D., Dyer, A., Cai, X., Garside, D. B., Ning, H., Thomas, A., Greenland, P., Van Horn, L., Tracy, R. P., & Lloyd-Jones, D. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1012848 · Cited by 945 · see citing works
Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815 · see citing works
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · see citing works
Association of Funding and Conclusions in Randomized Drug Trials: A Reflection of Treatment Effect or Adverse Events?
Als-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746 · see citing works
Investigating and Dealing with Publication and Other Biases
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch11 · Cited by 449 · see citing works
Self-citation
Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants
Ray, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446 · see citing works
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative
Culver, A. L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.625 · Cited by 444 · see citing works
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M. (2009) · Diabetes Care · doi:10.2337/dc09-0738 · Cited by 439 · see citing works
Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications
Martin, S. S., Blaha, M. J., Elshazly, M. B., Brinton, E. A., Toth, P. P., McEvoy, J. W., Joshi, P. H., Kulkarni, K. R., Mize, P. D., Kwiterovich, P. O., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.079 · Cited by 428 · see citing works
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416 · see citing works
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial
Heart Protection Study Collaborative Group (2011) · The Lancet · doi:10.1016/s0140-6736(11)61125-2 · Cited by 373 · see citing works
Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Charlton-Menys, V., DeMicco, D. A., & Fuller, J. H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.022 · Cited by 255 · see citing works
EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries
Kotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., Reiner, Ž., Keil, U., & EUROASPIRE Study Group (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283383f30 · Cited by 238 · see citing works
Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial
Hunt, D., Young, P., Simes, J., Hague, W., Mann, S., Owensby, D., Lane, G., Tonkin, A., & for the LIPID Investigators (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-10-200105150-00007 · Cited by 226 · see citing works
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV*
Lundgren, J., Battegay, M., Behrens, G., De Wit, S., Guaraldi, G., Katlama, C., Martinez, E., Nair, D., Powderly, W., Reiss, P., et al. (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2007.00534.x · Cited by 210 · see citing works
Should people at low risk of cardiovascular disease take a statin?
Abramson, J. D., Rosenberg, H. G., Jewell, N., & Wright, J. M. (2013) · BMJ · doi:10.1136/bmj.f6123 · Cited by 208 · see citing works
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA · doi:10.1001/jama.2012.8439 · Cited by 181 · see citing works
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease
Faergeman, O., Holme, I., Fayyad, R., Bhatia, S., Grundy, S. M., Kastelein, J. J. P., LaRosa, J. C., Larsen, M. L., Lindahl, C., Olsson, A. G., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.04.008 · Cited by 154 · see citing works
Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey
Reiner, Ž., Sonicki, Z., & Tedeschi-Reiner, E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.014 · Cited by 148 · see citing works
Statins for people at low risk of cardiovascular disease – Authors' reply
Mihaylova, B., Emberson, J., Keech, A., Collins, R., & Baigent, C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)62027-3 · Cited by 146 · see citing works
Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS)
Oikawa, S., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Sasaki, J., Hishida, H., Itakura, H., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.029 · Cited by 125 · see citing works
Drug Therapy in the Heart Transplant Recipient: Part IV: Drug–Drug Interactions
Page, R. L., Miller, G. G., & Lindenfeld, J. (2005) · Circulation · doi:10.1161/01.cir.0000151805.86933.35 · Cited by 100 · see citing works
High-risk elderly patients PROSPER from cholesterol-lowering therapy
Collins, R., & Armitage, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11650-3 · Cited by 42 · see citing works
Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: Analysis of data from the MEGA Study, a large randomized controlled trial
Uchiyama, S., Nakaya, N., Mizuno, K., Ohashi, Y., Tajima, N., Kushiro, T., Teramoto, T., & Nakamura, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.04.002 · Cited by 32 · see citing works
Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis
Ito, M. K., Nanchen, D., Rodondi, N., Paccaud, F., Waeber, G., Vollenweider, P., & Marques-Vidal, P. (2011) · American Journal Cardiovascular Drugs · doi:10.2165/11586760-000000000-00000 · Cited by 11 · see citing works

Flagged first, then by citations

Sorted by citations

2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536 · see citing works
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · see citing works
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185 · see citing works
2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works
2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536 · see citing works
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549 · see citing works
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162 · see citing works
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833 · see citing works
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691 · see citing works
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896 · see citing works
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857 · see citing works
Self-citation
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582 · see citing works
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
(2015) · The Lancet · doi:10.1016/s0140-6736(14)61368-4 · Cited by 1,536 · see citing works
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.009 · Cited by 1,193 · see citing works
The Oregon Experiment — Effects of Medicaid on Clinical Outcomes
Baicker, K., Taubman, S. L., Allen, H. L., Bernstein, M., Gruber, J. H., Newhouse, J. P., Schneider, E. C., Wright, B. J., Zaslavsky, A. M., & Finkelstein, A. N. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1212321 · Cited by 1,150 · see citing works
American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094 · see citing works
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064 · see citing works
Sex/Gender Differences in Cardiovascular Disease Prevention: What a Difference a Decade Makes
Mosca, L., Barrett-Connor, E., & Kass Wenger, N. (2011) · Circulation · doi:10.1161/circulationaha.110.968792 · Cited by 1,045 · see citing works
The Mediterranean Diet, its Components, and Cardiovascular Disease
Widmer, R. J., Flammer, A. J., Lerman, L. O., & Lerman, A. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.10.014 · Cited by 963 · see citing works
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
Mega, J. L., Stitziel, N. O., Smith, J. G., Chasman, D. I., Caulfield, M. J., Devlin, J. J., Nordio, F., Hyde, C. L., Cannon, C. P., Sacks, F. M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61730-x · Cited by 704 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706 · see citing works
Inequality and the health-care system in the USA
Dickman, S. L., Himmelstein, D. U., & Woolhandler, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30398-7 · Cited by 656 · see citing works
Natriuretic Peptide–Based Screening and Collaborative Care for Heart Failure: The STOP-HF Randomized Trial
Ledwidge, M., Gallagher, J., Conlon, C., Tallon, E., O’Connell, E., Dawkins, I., Watson, C., O’Hanlon, R., Bermingham, M., Patle, A., et al. (2013) · JAMA · doi:10.1001/jama.2013.7588 · Cited by 664 · see citing works
Discontinuation of Statins in Routine Care Settings: A Cohort Study
Zhang, H., Plutzky, J., Skentzos, S., Morrison, F., Mar, P., Shubina, M., & Turchin, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00004 · Cited by 548 · see citing works
Value of Primordial and Primary Prevention for Cardiovascular Disease: A Policy Statement From the American Heart Association
Weintraub, W. S., Daniels, S. R., Burke, L. E., Franklin, B. A., Goff, D. C., Hayman, L. L., Lloyd-Jones, D., Pandey, D. K., Sanchez, E. J., Schram, A. P., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182285a81 · Cited by 541 · see citing works
Lifestyle Interventions for Patients With and at Risk for Type 2 Diabetes: A Systematic Review and Meta-analysis
Schellenberg, E. S., Dryden, D. M., Vandermeer, B., Ha, C., & Korownyk, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-8-201310150-00007 · Cited by 520 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471 · see citing works
How to Read a Systematic Review and Meta-analysis and Apply the Results to Patient Care: Users’ Guides to the Medical Literature
Murad, M. H., Montori, V. M., Ioannidis, J. P. A., Jaeschke, R., Devereaux, P. J., Prasad, K., Neumann, I., Carrasco-Labra, A., Agoritsas, T., Hatala, R., et al. (2014) · JAMA · doi:10.1001/jama.2014.5559 · Cited by 454 · see citing works
Digital health interventions for the prevention of cardiovascular disease: a systematic review and meta-analysis
Widmer, R. J., Collins, N. M., Collins, C. S., West, C. P., Lerman, L. O., & Lerman, A. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.12.026 · Cited by 416 · see citing works
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Schmidt, A. F., Swerdlow, D. I., Holmes, M. V., Patel, R. S., Fairhurst-Hunter, Z., Lyall, D. M., Hartwig, F. P., Horta, B. L., Hyppönen, E., Power, C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30396-5 · Cited by 380 · see citing works
Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities
Jakobsen, G. S., Småstuen, M. C., Sandbu, R., Nordstrand, N., Hofsø, D., Lindberg, M., Hertel, J. K., & Hjelmesæth, J. (2018) · JAMA · doi:10.1001/jama.2017.21055 · Cited by 358 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339 · see citing works
Meditation and Cardiovascular Risk Reduction: A Scientific Statement From the American Heart Association
Levine, G. N., Lange, R. A., Bairey‐Merz, C. N., Davidson, R. J., Jamerson, K., Mehta, P. K., Michos, E. D., Norris, K., Ray, I. B., Saban, K. L., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.002218 · Cited by 330 · see citing works
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Anstee, Q. M., Mantovani, A., Tilg, H., & Targher, G. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0010-0 · Cited by 310 · see citing works
Mining Electronic Health Records (EHRs): A Survey
Yadav, P., Steinbach, M., Kumar, V., & Simon, G. (2018) · ACM Computing Surveys · doi:10.1145/3127881 · Cited by 299 · see citing works
Use of Mendelian randomisation to assess potential benefit of clinical intervention.
Burgess, S., Butterworth, A., Malarstig, A., & Thompson, S. G. (2012) · BMJ · doi:10.1136/bmj.e7325 · Cited by 292 · see citing works
Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials
Naci, H., Brugts, J., & Ades, T. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000071 · Cited by 292 · see citing works
UK Biobank: Opportunities for cardiovascular research
Littlejohns, T. J., Sudlow, C., Allen, N. E., & Collins, R. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehx254 · Cited by 270 · see citing works
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304 · see citing works
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study
Ford, I., Murray, H., McCowan, C., & Packard, C. J. (2016) · Circulation · doi:10.1161/circulationaha.115.019014 · Cited by 238 · see citing works
Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease
Savarese, G., Gotto, A. M., Paolillo, S., D'Amore, C., Losco, T., Musella, F., Scala, O., Marciano, C., Ruggiero, D., Marsico, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.069 · Cited by 219 · see citing works
Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data
Matthews, A., Herrett, E., Gasparrini, A., Van Staa, T., Goldacre, B., Smeeth, L., & Bhaskaran, K. (2016) · BMJ · doi:10.1136/bmj.i3283 · Cited by 221 · see citing works
Resistance and intolerance to statins
Reiner, Ž. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.009 · Cited by 225 · see citing works
Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study
Kokkinos, P. F., Faselis, C., Myers, J., Panagiotakos, D., & Doumas, M. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61426-3 · Cited by 217 · see citing works
9. Cardiovascular Disease and Risk Management
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s012 · Cited by 223 · see citing works
What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice
Finegold, J. A., Manisty, C. H., Goldacre, B., Barron, A. J., & Francis, D. P. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314525531 · Cited by 214 · see citing works
Should people at low risk of cardiovascular disease take a statin?
Abramson, J. D., Rosenberg, H. G., Jewell, N., & Wright, J. M. (2013) · BMJ · doi:10.1136/bmj.f6123 · Cited by 208 · see citing works
Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials
Naci, H., Brugts, J. J., Fleurence, R., Tsoi, B., Toor, H., & Ades, A. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313480435 · Cited by 202 · see citing works
Effects of Coenzyme Q10 on Statin-Induced Myopathy
Banach, M., Serban, C., Sahebkar, A., Ursoniu, S., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Glasser, S. P., et al. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.08.021 · Cited by 198 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192 · see citing works
Serum C-reactive protein in the prediction of cardiovascular diseases: overview of the latest clinical studies and public health practice
Avan, A., Tavakoly Sany, S. B., Ghayour‐Mobarhan, M., Rahimi, H. R., Tajfard, M., & Ferns, G. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26791 · Cited by 182 · see citing works
The NHS Health Check in England: an evaluation of the first 4 years
Robson, J., Dostal, I., Sheikh, A., Eldridge, S., Madurasinghe, V., Griffiths, C., Coupland, C., & Hippisley-Cox, J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-008840 · Cited by 184 · see citing works
A systematic review and meta-analysis of nut consumption and incident risk of CVD and all-cause mortality
Mayhew, A. J., de Souza, R. J., Meyre, D., Anand, S. S., & Mente, A. (2016) · British Journal Of Nutrition · doi:10.1017/s0007114515004316 · Cited by 147 · see citing works
Statins, cognition, and dementia-systematic review and methodological commentary
Power, M. C., Weuve, J., Sharrett, A. R., Blacker, D., & Gottesman, R. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.35 · Cited by 150 · see citing works
A systematic review of patient reported factors associated with uptake and completion of cardiovascular lifestyle behaviour change
Murray, J., Craigs, C. L., Hill, K. M., Honey, S., & House, A. (2012) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-12-120 · Cited by 138 · see citing works
Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis
Yourman, L. C., Cenzer, I. S., Boscardin, W. J., Nguyen, B. T., Smith, A. K., Schonberg, M. A., Schoenborn, N. L., Widera, E. W., Orkaby, A., Rodriguez, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6084 · Cited by 133 · see citing works
Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry
Nanna, M. G., Navar, A. M., Zakroysky, P., Xiang, Q., Goldberg, A. C., Robinson, J., Roger, V. L., Virani, S. S., Wilson, P. W. F., Elassal, J., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1511 · Cited by 122 · see citing works
A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia
Li, Y., Jiang, L., Jia, Z., Xin, W., Yang, S., Yang, Q., & Wang, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098611 · Cited by 124 · see citing works
An assessment by the Statin Diabetes Safety Task Force: 2014 update
Maki, K. C., Ridker, P. M., Brown, W. V., Grundy, S. M., & Sattar, N. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.02.012 · Cited by 119 · see citing works
Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis
Byrne, P., Demasi, M., Jones, M., Smith, S. M., O’Brien, K. K., & DuBroff, R. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0134 · Cited by 114 · see citing works
Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies
Colantonio, L. D., Bittner, V., Reynolds, K., Levitan, E. B., Rosenson, R. S., Banach, M., Kent, S. T., Derose, S. F., Zhou, H., Safford, M. M., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.011646 · Cited by 105 · see citing works
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., & Ford, I. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht232 · Cited by 104 · see citing works
Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature
Yu, M., Liang, C., Kong, Q., Wang, Y., & Li, M. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-019-1182-5 · Cited by 107 · see citing works
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109 · see citing works
Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide
Pokharel, Y., Tang, F., Jones, P. G., Nambi, V., Bittner, V. A., Hira, R. S., Nasir, K., Chan, P. S., Maddox, T. M., Oetgen, W. J., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.5922 · Cited by 107 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107 · see citing works
Statins are associated with increased insulin resistance and secretion
Abbasi, F., Lamendola, C., Harris, C. S., Harris, V., Tsai, M.-S., Tripathi, P., Abbas, F., Reaven, G. M., Reaven, P. D., Snyder, M. P., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316159 · Cited by 98 · see citing works
Trends in treatment and mortality for mesenteric ischemia in the United States from 2000 to 2012
Zettervall, S. L., Lo, R. C., Soden, P. A., Deery, S. E., Ultee, K. H., Pinto, D. S., Wyers, M. C., & Schermerhorn, M. L. (2017) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2017.01.007 · Cited by 88 · see citing works
Healthy ageing through internet counselling in the elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment
Richard, E., Jongstra, S., Soininen, H., Brayne, C., Moll van Charante, E. P., Meiller, Y., van der Groep, B., Beishuizen, C. R. L., Mangialasche, F., Barbera, M., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010806 · Cited by 92 · see citing works
Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis
Ross, S., D’Mello, M., Anand, S. S., Eikelboom, J., CARDIoGRAMplusC4D Consortium*, Stewart, A. F. R., Samani, N. J., Roberts, R., & Paré, G. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000952 · Cited by 90 · see citing works
Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89 · see citing works
Statin Trials, Cardiovascular Events, and Coronary Artery Calcification
Mortensen, M. B., Falk, E., Li, D., Nasir, K., Blaha, M. J., Sandfort, V., Rodriguez, C. J., Ouyang, P., & Budoff, M. (2018) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2017.01.029 · Cited by 88 · see citing works
PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016
Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86 · see citing works
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease
Gotto, A. M., Cannon, C. P., Li, X. S., Vaidya, S., Kher, U., Brinton, E. A., Davidson, M., Moon, J. E., Shah, S., Dansky, H. M., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.041 · Cited by 86 · see citing works
PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites
Kent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., et al. (2017) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001632 · Cited by 86 · see citing works
Artificial intelligence for detection of cardiovascular-related diseases from wearable devices: A systematic review and meta-analysis
Lee, S., Chu, Y., Ryu, J., Park, Y. J., Yang, S., & Koh, S. B. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.s93 · Cited by 88 · see citing works
Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry
Nanna, M. G., Navar, A. M., Wang, T. Y., Mi, X., Virani, S. S., Louie, M. J., Lee, L. V., Goldberg, A. C., Roger, V. L., Robinson, J., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008546 · Cited by 82 · see citing works
A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications
Beary, M., Hodgson, R., & Wildgust, H. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112440512 · Cited by 79 · see citing works
The impact of statins on psychological wellbeing: a systematic review and meta-analysis
O'Neil, A., Sanna, L., Redlich, C., Sanderson, K., Jacka, F., Williams, L. J., Pasco, J. A., & Berk, M. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-154 · Cited by 78 · see citing works
Results from a clinical yoga program for veterans: yoga via telehealth provides comparable satisfaction and health improvements to in-person yoga
Schulz-Heik, R. J., Meyer, H., Mahoney, L., Stanton, M. V., Cho, R. H., Moore-Downing, D. P., Avery, T. J., Lazzeroni, L. C., Varni, J. M., Collery, L. M., et al. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1705-4 · Cited by 77 · see citing works
Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study
Šabovič, M. (2014) · Medical Science Monitor · doi:10.12659/msm.890777 · Cited by 75 · see citing works
PCSK9 inhibitor therapy: A systematic review and meta‐analysis of metabolic and cardiovascular outcomes in patients with diabetes
Monami, M., Sesti, G., & Mannucci, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13599 · Cited by 58 · see citing works
Emulating a target trial of statin use and risk of dementia using cohort data
Caniglia, E. C., Rojas-Saunero, L. P., Hilal, S., Licher, S., Logan, R., Stricker, B., Ikram, M. A., & Swanson, S. A. (2020) · Neurology · doi:10.1212/wnl.0000000000010433 · Cited by 56 · see citing works
ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0697-3 · Cited by 54 · see citing works
Microbiota and the nitrogen cycle: Implications in the development and progression of CVD and CKD
Briskey, D., Tucker, P. S., Johnson, D. W., & Coombes, J. S. (2016) · Nitric Oxide · doi:10.1016/j.niox.2016.05.002 · Cited by 47 · see citing works
Simvastatin treatment exerts antidepressant-like effect in rats exposed to chronic mild stress
Lin, P.-Y., Chang, A. Y. W., & Lin, T.-K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.06.006 · Cited by 43 · see citing works
Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies
Mitchell, S., Roso, S., Samuel, M., & Pladevall-Vila, M. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0241-3 · Cited by 40 · see citing works
Primary prevention of cardiovascular disease with statins in the elderly
Reiner, Ž. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0420-6 · Cited by 38 · see citing works
Do Statins Have Antidepressant Effects?
Köhler-Forsberg, O., Gasse, C., Berk, M., & Østergaard, S. D. (2017) · CNS Drugs · doi:10.1007/s40263-017-0422-3 · Cited by 31 · see citing works
Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Apparent Treatment‐Resistant Hypertension
Egan, B. M., Kai, B., Wagner, C. S., Henderson, J. H., Chandler, A. H., & Sinopoli, A. (2016) · The Journal of Clinical Hypertension · doi:10.1111/jch.12773 · Cited by 32 · see citing works
Reasons for (non)compliance with intervention following identification of 'high-risk' status in the NHS Health Check programme
McNaughton, R. J., & Shucksmith, J. (2015) · Journal of Public Health · doi:10.1093/pubmed/fdu066 · Cited by 30 · see citing works
Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia
Reiner, Ž. (2014) · Circulation Research · doi:10.1161/circresaha.113.302952 · Cited by 26 · see citing works
Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from the irish longitudinal study on ageing (TILDA)
Murphy, C., Bennett, K., Fahey, T., Shelley, E., Graham, I., & Kenny, R. A. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008017 · Cited by 25 · see citing works
Risk of diabetes with statins
Mansi, I. A., Sumithran, P., & Kinaan, M. (2023) · BMJ · doi:10.1136/bmj-2022-071727 · Cited by 20 · see citing works
Association Between Poverty and Appropriate Statin Prescription for the Treatment of Hyperlipidemia in the United States: An Analysis From the ACC NCDR PINNACLE Registry
Tanguturi, V. K., Kennedy, K. F., Virani, S. S., Maddox, T. M., Armstrong, K., & Wasfy, J. H. (2020) · Cardiovascular Revascularization Medicine · doi:10.1016/j.carrev.2019.12.026 · Cited by 14 · see citing works
Preventive service use among people with and without serious mental illnesses.
Yarborough, B. J. H., Perrin, N. A., Stumbo, S. P., Muench, J., & Green, C. A. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.08.020 · Cited by 13 · see citing works

Authors: Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C.
Affiliations: London School of Hygiene & Tropical Medicine (GB)
Northwestern University (US)
University of Beira Interior (PT)
University of Bristol (GB)
MRC Integrative Epidemiology Unit, School of Social and Community Medicine; University of Bristol; Bristol UK
King's College London (GB)
ORCID: Taylor, Fiona
Huffman, Mark D
Moore, Theresa HM
Ward, Kirsten
Ebrahim, Shah
Gay, Hawkins C
Venue: Cochrane Database of Systematic Reviews
Publisher: Wiley
Published: 2013-01-31
Volume: 2021
Issue: 9
Pages: CD004816-CD004816
ISSN: 1361-6137 (ISSN-L)
1465-1858
DOI: 10.1002/14651858.cd004816.pub5
PMC: PMC6481400
OpenAlex: W1816597323
Cited by: 1,934
References: 37
Citations by year: 2026: 17 · 2025: 54 · 2024: 80 · 2023: 82 · 2022: 62 · 2021: 103 · 2020: 127 · 2019: 141 · 2018: 149 · 2017: 173 · 2016: 228 · 2015: 199 · 2014: 211 · 2013: 167 · 2012: 83
FWCI: 47.52
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cochrane Database of Systematic Reviews (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: National Institute for Health and Care Research
Topics: Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords: statins, primary prevention, cardiovascular disease, all-cause mortality, cardiovascular events, stroke, coronary artery disease, LDL cholesterol, HDL cholesterol, lipid-lowering therapy, adverse events, quality of life, cost-effectiveness, diabetes mellitus, hypertension, microalbuminuria, hypercholesterolemia, statin safety, statin efficacy, revascularization, quality-adjusted life years
MeSH terms: Adult, Cardiovascular Diseases, Cause of Death, Humans, Cholesterol, HDL, Cholesterol, LDL, Myocardial Revascularization, Primary Prevention, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Statins for the primary prevention of cardiovascular disease

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Record

About these checks